Anti-diabetic-oral-hypoglycemic-drugs
Pharmacologic Approaches to
Glycemic Treatment:
The goals
in caring for patients with diabetes mellitus are to eliminate symptoms and to
prevent, or at least slow, the development of complications. FIND BELOW TREATMENT RECOMMENDATIONS FOR TYPE 2 DIABETES:
Journal of Diabetes and its Complications: September
2023Kidney disease is a diabetes-related
complication and diabetes is the most common cause of end-stage kidney disease
(ESKD) in the world.This study analyzed the incidence of kidney disease in the
Diabetes Prevention Program Outcomes Study.TAKE-HOME MESSAGEAfter 21
years of randomization i...
Diabetes, Obesity &
Metabolism Journal: Published:
December 2023Type 2 diabetes (T2D) and liver diseases are closely
associated. T2D is an independent risk factor for chronic liver diseases,
including metabolic dysfunction-associated steatotic liver disease (MASLD),
non-alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma...
Diabetes Care: May, 2023Type 2 diabetes is associated with
increased risk of microvascular and macrovascular disease, with the risk of
cardiovascular (CV) mortality more than double in people with type 2 diabetes
compared with those without. In the last decade, large dedicated
CV outcome trials in people with type 2 diabetes and at high risk or...
JAMA Internal Medicine: Published on May, 2023Diabetic kidney disease is the leading cause of chronic
kidney disease and end-stage kidney failure in the vast majority of the
world. TAKE-HOME MESSAGEThis randomized clinical trial evaluated the use of
glucose-lowering medications on kidney outcomes. A total of 5047 patients with type 2 diabet...
The Lancet Diabetes & Endocrinology: Published on
February, 2023Metformin is increasingly being
used during pregnancy, with potentially adverse long-term effects on children. This study aimed to examine
adiposity in children of women with type 2 diabetes from the Metformin in Women
with Type 2 Diabetes in Pregnancy (MiTy) trial, with and withou...
Clinical Diabetes and Endocrinology Journal: Published: May 2022Diabetes Mellitus (DM) is a debilitating metabolic disorder
characterized by impaired insulin function, leading to chronic hyperglycemia.Diabetic nephropathy (DN) is one of the most common and
severe microvascular complications of DM, occurring in about 20–30% of diabetic
patients,...
Diabetes, Obesity and Metabolism Journal:
PubMedTAKE HOME MESSAGE:The study aims to investigate the
effect of sequential treatment escalation with empagliflozin and linagliptin on
laboratory markers of α- and β-cell function in people with type 2 diabetes
mellitus (T2DM) insufficiently controlled on metformin monotherapy.The researchers found t...
AHA Journals: Hypertension: Published on May, 2022Diabetes is a strong risk factor
for end-stage renal disease (ESRD). Hypertension also plays a crucial role
in the development and progression of kidney failure. Blood pressure (BP)
rises with declining kidney function which in turn aggravates hypertension. Moreover, as chronic kidney disease
(C...
Coronavirus disease 2019 (COVID-19)
is one of the most significant pandemics in human history caused by the virus
known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 has infected >530 million people, of which >6.3 million have
died since June 23, 2022. Recent research has indicated that
COVID-19 might be a risk fa...
Diabetes Research and
Clinical Practice: Published
on July, 2022The American Diabetes Association recommends that metformin
should be started at the time of type 2 diabetes mellitus (T2DM) diagnosis,
unless there are contraindications. Metformin is safe, effective, economic,
and might reduce the risk of cardiovascular events and death. When gl...
ADA Diabetes Care Journal:
Metformin
is the recommended first-line pharmacotherapy for patients with type 2 diabetes,
but most patients will ultimately require additional therapies to maintain
glycemic control.
Maintaining
intensive glucose control early in the disease process may lead to legacy
benefits that persist beyond the per...
